替尔泊肽与2型糖尿病参与者白蛋白尿降低相关:随机活性对照和安慰剂对照SURPASS-1-5临床试验的汇总事后分析
该事后分析汇总SURPASS-1-5试验数据,评估替尔泊肽5、10、15 mg与对照相比对UACR的影响。第40/42周时,替尔泊肽各剂量组UACR较基线分别降低19.3%、22.0%和26.3%,eGFR无差异。作者认为替尔泊肽与UACR临床相关下降有关,可能具有肾脏保护作用。
要点
- 替尔泊肽5、10、15 mg组第40/42周UACR较基线分别降低19.3%、22.0%、26.3%(vs 汇总对照)。
- UACR≥30 mg/g亚组中UACR降低似乎更明显。
- 中介分析提示约一半的白蛋白尿降低可能与体重减轻相关。
核心结论
- 在2型糖尿病(包括慢性肾脏病)人群中,替尔泊肽与对照相比UACR临床相关降低,提示潜在肾脏保护作用。
研究设计与样本
- SURPASS-1-5随机活性对照和安慰剂对照试验的汇总事后分析,评估总体汇总人群及基线UACR≥30 mg/g亚组。
- 采用重复测量混合模型分析从基线至治疗结束访视的on-treatment数据,模型中将研究标识作为协变量。
主要发现
- 第40/42周时,替尔泊肽5 mg组UACR较基线变化为-19.3%(95% CI -25.5, -12.5),10 mg组为-22.0%(-28.1, -15.3),15 mg组为-26.3%(-32.0, -20.0),均对比所有汇总对照。
- 结果在汇总安慰剂、活性药物和胰岛素对照研究中相似。
- UACR≥30 mg/g亚组中UACR降低似乎更明显。
- 中介分析提示替尔泊肽相关白蛋白尿降低中约一半可能与体重减轻相关。
- 第40/42周时替尔泊肽与汇总对照之间eGFR无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tirzepatide, a long-acting, glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, reduced urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) decline in people with type 2 diabetes and high cardiovascular risk in the SURPASS-4 trial. To examine the generalizability of these findings, we assessed change from baseline in UACR for tirzepatide (5, 10, and 15 mg) compared with active and placebo treatment in a broad population from the SURPASS-1-5 trials. RESEARCH DESIGN AND METHODS: This post hoc analysis examined data from the overall pooled SURPASS-1-5 population and subgroups defined by baseline UACR ≥30 mg/g. A mixed model for repeated measures was used to analyze on-treatment data from baseline to the end-of-treatment visit. Study identifier was included in the model as a covariate. RESULTS: The adjusted mean percent change from baseline in UACR for tirzepatide 5, 10, or 15 mg compared with all pooled comparators was -19.3% (95% CI -25.5, -12.5), -22.0% (-28.1, -15.3), and -26.3 (-32.0, -20.0), respectively, at week 40/42. Results were similar across pooled placebo, active, and insulin comparator studies. UACR lowering appeared more pronounced in subgroups with UACR ≥30 mg/g. Mediation analysis findings suggested that approximately one-half of the reduction in albuminuria associated with tirzepatide may be weight loss related. There was no difference in eGFR between tirzepatide and pooled comparators at week 40/42. CONCLUSIONS: In this post hoc analysis in people with type 2 diabetes, including those with chronic kidney disease, tirzepatide was associated with a clinically relevant decreased UACR versus comparators, suggesting a potential kidney-protective effect.
引用
- Apperloo EM, Tuttle KR, Pavo I, et al. Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials. Diabetes Care. 2025. PMID: 39746157. doi:10.2337/dc24-1773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。